Xenon Pharmaceuticals (XENE) Operating Leases (2019 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Operating Leases of $5.9 million for Q1 2026, down 18.69% year-over-year from $7.3 million in Q1 2025, and down 7.52% quarter-over-quarter from $6.4 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Operating Leases (2019 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Operating Leases for 8 consecutive years, with $5.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 18.69% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $5.9 million (down 18.69% YoY), while the FY2025 annual figure was $6.4 million, down 16.14% from the prior year.
- Operating Leases declined to $5.9 million in Q1 2026 per XENE's latest filing, from $6.4 million in the prior quarter.
- Across five years, Operating Leases topped out at $10.4 million in Q1 2023 and bottomed at $5.9 million in Q1 2026.
- Historically, Operating Leases has averaged $8.3 million across 5 years, with a median of $8.2 million in 2022.
- Annual changes were most pronounced in 2022 — Operating Leases soared 185.91% — and 2024, when it fell 20.39%.
- Xenon Pharmaceuticals' Operating Leases stood at $9.9 million in 2022, then slipped by 3.45% to $9.6 million in 2023, then dropped by 20.39% to $7.6 million in 2024, then fell by 16.14% to $6.4 million in 2025, then declined by 7.52% to $5.9 million in 2026.
- Business Quant data shows XENE's Operating Leases at $5.9 million in Q1 2026, $6.4 million in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.08 Mn |
| Mar 31, 2026 | 5.93 Mn |
| Dec 31, 2025 | 6.41 Mn |
| Sep 30, 2025 | 6.83 Mn |
| Jun 30, 2025 | 7.26 Mn |
| Mar 31, 2025 | 7.29 Mn |
| Dec 31, 2024 | 7.65 Mn |
| Sep 30, 2024 | 8.40 Mn |
| Jun 30, 2024 | 8.68 Mn |
| Mar 31, 2024 | 9.10 Mn |
| Dec 31, 2023 | 9.60 Mn |
| Sep 30, 2023 | 9.76 Mn |
| Jun 30, 2023 | 10.28 Mn |
| Mar 31, 2023 | 10.43 Mn |
| Dec 31, 2022 | 9.95 Mn |
| Sep 30, 2022 | 7.16 Mn |
| Jun 30, 2022 | 7.85 Mn |
| Mar 31, 2022 | 8.22 Mn |
| Dec 31, 2021 | 7.65 Mn |
| Sep 30, 2021 | 2.56 Mn |